Beta2 agonists reduce airway hypersensitivity to bronchoconstrictor stimuli acutely in patients with asthma and chronic obstructive lung disease. To determine whether these drugs also protect against excessive airway narrowing, the effect of inhaled salbutamol on the position and shape of the doseresponse curve for histamine or methacholine was investigated in 12 patients with asthma and 11 with chronic obstructive lung disease. After pretreatment with salbutamol (200 or 400 pg) or placebo in a double blind manner doseresponse curves for inhaled histamine and methacholine were obtained by a standard method on six days in random order. Airway sensitivity was defined as the concentration of histamine or methacholine causing a 20% fall in FEV, (PC20). A maximal response plateau on the log dose-response curve was considered to be present if two or more data points for FEV, fell within a 5% response range. In
Abstract
Beta2 agonists reduce airway hypersensitivity to bronchoconstrictor stimuli acutely in patients with asthma and chronic obstructive lung disease. To determine whether these drugs also protect against excessive airway narrowing, the effect of inhaled salbutamol on the position and shape of the doseresponse curve for histamine or methacholine was investigated in 12 patients with asthma and 11 with chronic obstructive lung disease. After pretreatment with salbutamol (200 or 400 pg) or placebo in a double blind manner doseresponse curves for inhaled histamine and methacholine were obtained by a standard method on six days in random order. Airway sensitivity was defined as the concentration of histamine or methacholine causing a 20% fall in FEV, (PC20) . A maximal response plateau on the log dose-response curve was considered to be present if two or more data points for FEV, fell within a 5% response range. In the absence of a plateau, the test was continued until a predetermined level of severe bronchoconstriction was reached. Salbutamol caused an acute increase in FEV1 (mean increase 11l5% predicted in asthma, 7-2% in chronic obstructive lung disease), an increase in PC20 (mean 15 fold in asthma, fivefold in chronic obstructive lung disease), and an increase in the slope of the dose-response curves in both groups. In subjects in whom a plateau of FEV, response could be measured salbutamol did not change the level of the plateau. In subjects without a plateau salbutamol did not lead to the development of a plateau, despite achieving a median FEV, of 44% predicted in asthma and 39% in chronic obstructive lung disease. These results show that, although beta2 agonists acutely reduce the airway response to a given strength of bronchoconstrictor stimulus, they do not protect against excessive airflow obstruction if there is exposure to relatively strong stimuli. This, together with the steepening of the dose-response curve, could be a disadvantage of beta2 agonists in the treatment of moderate and severe asthma or chronic obstructive lung disease.
Airway hyperresponsiveness is an almost universal feature of patients with symptomatic asthma'2 and is common among patients with chronic obstructive lung disease.34 Hyperresponsiveness is usually defined as an increased sensitivity of the airways to inhaled non-sensitising bronchoconstrictor stimuli. Increased sensitivity is reflected by a leftward shift of the dose-response curve for inhaled histamine or methacholine, so that a smaller dose of agonist produces the same response of the airways.5 There is accumulating evidence that airway hyperresponsiveness is a more complex functional abnormality that comprises more than just hypersensitivity.6 Apart from a leftward shift, the shape of the doseresponse curve for inhaled stimuli also differs between asthmatic and normal subjects.7 In normal subjects the dose-response curve achieves a plateau at mild degrees of airway narrowing,7 8 whereas in asthmatic subjects excessive degrees of airway narrowing can be obtained without the achievement of a plateau response. 7 From a clinical point of view excessive airway narrowing may be a more troublesome and hazardous feature than increased airway sensitivity as such. 9 We might therefore argue that treatment of patients with airway hyperresponsiveness should be directed not only towards shifting the dose-response curve to the right but also towards preventing excessive airway narrowing.
Bronchodilators such as beta2 agonists are recommended as first choice drugs in the management of asthma and chronic obstructive lung disease,'0 and are the most effective drugs available for acutely shifting the bronchoconstrictor dose-response curves to the right." It is uncertain, however, whether bronchodilators also protect against excessive airway narrowing. We have therefore studied the effects of inhaled salbutamol on the position and the shape of the dose-response curves for histamine and methacholine in hyperresponsive patients with asthma or chronic obstructive lung disease.
Methods

SUBJECTS
Twelve patients with asthma and 11 with chronic obstructive lung disease volunteered to participate in the study. The asthmatic subjects (10 men and two women, mean age 24-9 (range 22-32) years) had a history of episodic chest tightness or wheezing, were atopic (more than one weal response to skinprick tests with 13 common allergens), and were lifelong nonsmokers. Their mean forced expiratory volume in one second (FEVI) was 82-7% (range 67-2-107 3%) of the predicted value,'2 whereas the postbronchodilator (400 jug inhaled salbutamol) FEV, and ratio of FEVy to vital capacity (FEVI/VC) were within the predicted range.'2 The geometric mean provocative concentration of inhaled methacholine that caused a 20% fall in FEV, (PC20) was 0-94 (range 0-11-2 86) mg/ml. 5 The subjects with chronic obstructive lung disease (10 men The slope of the sigmoid shaped dose-response curve was calculated by linear regression analysis of the data points used to calculate the PC20 plus all consecutive data points up to the last point in the absence of a plateau, or up to the first point on the plateau. A maximal response plateau was considered to be present if two or more of the highest doses fell within a 5% response range; the maximum response was then calculated by averaging the consecutive data points on the plateau.8 If a plateau could not be measured, the last of the data points of the dose-response curve (lowest FEVy) was used in the analysis, provided that the challenge limit (± 5 %), as determined at the screening visit, was reached. Analysis of variance and Student's unpaired and paired t tests were used to analyse differences in the natural log PC20 or log slope between and within groups. McNemar tests were used to analyse differences in the lowest FEV,.
Values of p below 0 05 were considered statistically significant.
Results
BRONCHODILATATION
The mean (SD) baseline FEVy was 83% (11 %) predicted in the group with asthma and 62% (12%) predicted in the group with chronic obstructive lung disease. The mean (SD) increase in FEVy after 200 jg salbutamol was 11-5% (7 8%) predicted in the subjects with asthma and 6-9% (7 5%) predicted in those with chronic obstructive lung disease; after 400 jg salbutamol the mean increases were 11-0% (7-8%) and 7-2% (9-7%) predicted.
BRONCHOCONSTRICTOR DOSE-RESPONSE CURVES
Representative dose-response curves for histamine and methacholine after the different treatments in one subject with asthma and one subject with chronic obstructive lung disease are shown in figure 1.
AIRWAY SENSITIVITY
The geometric mean PC20 (SD in doubling -3) (fig 1) . Methacholine (mg/ml) and methacholine curves were, however, significantly steeper in patients with asthma than in those with chronic obstructive lung disease (p < 0-05; fig 1) . After 200 ig and 400 ug salbutamol there was an increase in the slope of the curves for histamine and methacholine in each group (p < 0-02). There was a positive correlation between the increase in FEV, and the increase in slope of the methacholine and histamine curves in asthma (p < 0 05) and in chronic obstructive lung disease (p < 0-01).
Discussion
This study shows that, although inhaled salbutamol increases baseline airway calibre acutely and decreases the sensitivity of the airways to bronchoconstrictor stimuli, it does not protect against excessive airway narrowing. On the contrary, the slope of the dose-response curves for histamine and methacholine were steeper after salbutamol, implying a more rapid increase in airflow obstruction should there be exposure to high doses of bronchoconstrictor stimuli. This raises questions about the value of beta2 agonists in the treatment of asthma and chronic obstructive lung disease. This is the first study in which the protective effect of a beta2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli has been investigated. Most previous reports have focused on the influence of bronchodilators on the sensitivity of the airways to inhaled bronchoconstrictors. 4 1 1625 In these studies beta2 agonists have been shown to shift the dose-response curve by about 2-4 *doubling doses in asthma"1 [16] [17] [18] [19] [20] [21] [22] [23] and by about 0 5-2 5 doubling doses in chronic obstructive lung disease.2425 The results of the present study confirm these data, showing a greater rightward shift of the dose-response curve in asthma than in chronic obstructive lung disease. Our results show that the shift ofthe doseresponse curve is unrelated to the degree of bronchodilatation induced by salbutamol. This was not found by others,22 perhaps owing to differences in salbutamol doses. We were, however, able to confirm that the shift of the curve is greatest in the most sensitive subjects.'82' The results of the present study show only a small dose-effect relationship of salbutamol and sensitivity to histamine and methacholine. This might be due to the relatively small increment in the salbutamol dose or to domination of the spasmogenic activity of methacholine and histamine over the relaxing capacity of salbutamol.26 This is in accordance with the results from studies on airway smooth muscle in vitro, in which relative resistance of submaximal contractions to the relaxant effect of beta2 agonists has been observed.2627 Overall our observations show the varying potency of the beta2 adrenergic bronchodilator salbutamol in protecting against hypersensitivity to bronchoconstrictor stimuli.
The main finding of the present study is the lack of any effect of salbutamol on excessive degrees of airflow obstruction to inhaled histamine or methacholine in asthma and chronic obstructive lung disease. In the subjects in whom a maximal response plateau could be measured, the beta2 adrenergic agent appeared not to change the presence of the plateau or its level. And in those subjects in whom a plateau could not be measured salbutamol pretreatment did not lead to the development of a plateau, despite achieving a median fall in FEV1 down to 44% (asthma) and 39% (chronic obstructive lung disease) predicted, compared with 43% and 36% respectively after placebo. Despite a return of PC20 values into the normal range after salbutamol in some instances, patients still had excessive airway narrowing in response to higher doses ofhistamine or methacholine. This is in sharp contrast to normal subjects, who at similar degrees of airway sensitivity show a plateau response at mild degrees of airway narrowing when exposed to high doses of histamine or methacholine.28 As appears from modelling studies29 and experimental evidence,6 the.maximal degree of airway narrowing is determined not only by intrinsic contractility of airway smooth muscle and the mechanical load the muscle has to overcome during contraction but also by the thickness of the airway wall. Swelling of the airway wall secondary to inflammatory processes has been reported both in asthma30 and chronic obstructive lung disease.3' Apparently salbutamol did not acutely affect this later mechanism. This is in accordance with its mode of action as it is a functional antagonist of histamine and methacholine on smooth muscle contraction.
Besides position and shape, the slope of the dose-response curve is another index of the in vivo response to bronchoconstrictor stimuli. In the present study there was an increase in slope of the histamine and methacholine doseresponse curve after salbutamol, both in the patients with asthma and in those with chronic obstructive lung disease. In previous studies investigating the effects of beta2 agonists on the slope of the dose-response curves for histamine and methacholine in asthma the results have been controversial,'1-2' perhaps owing to the method of expressing the response (% fall from baseline or predicted value),2' or to there being a smaller number of data points on the curves than in the present study. The reasons for the increase in slope after inhalation of salbutamol are not clear. They may be related to differences in drug penetration and deposition between dilated and constricted airways,32 or to an increase in mucosal thickness induced by the higher doses of histamine and methacholine or by salbutamol itself.33
Apart from the effect of beta2 agonists, this study shows differences between asthma and chronic obstructive lung disease in the position and shape of the dose-response curves for histamine and methacholine. Firstly, asthmatic patients were equally sensitive to histamine and methacholine, whereas patients with chronic obstructive lung disease were more sensitive to histamine than to methacholine, as found previously.34 Secondly, there was a steeper slope of the dose-response curves in asthma than in chronic obstructive lung disease, fitting in with the characteristic symptoms of asthma (wide variations in airflow over short periods of time). Thirdly, only a few subjects with chronic obstructive lung disease reached a maximal response plateau on the dose-response curve for methacholine. The lack of a plateau in most of our subjects could be explained by increased airway wall thickness in chronic obstructive lung disease.3' Our findings are not, however, in agreement with an earlier study of smokers with hyperresponsive airways, most of whom showed a plateau in their dose-response curve for methacholine. 3 We have no explanation for these discrepant results. They could be due to different selection criteria of the subjects, yielding more severe airflow obstruction in our study.
The results of the present study have clinical implications. Firstly, beta2 agonists only partially protect against airway narrowing in patients with asthma or chronic obstructive lung disease exposed to strong stimuli. Even when airway sensitivity has returned to normal 
